A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive patients.

Objective: to explain anti-HBc is a new predictor of peginterferon treatment response.

Type of research: clinical trial.

Method of data collection: Serum samples were collected every 12 weeks, and were tested.

Type of data: clinical data.